Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 4/20 | 0.31 |
| ▸ | JAK2 | O60674 | 2/20 | 0.31 |
| ▸ | TYK2 | P29597 | 2/20 | 0.31 |
| ▸ | JAK3 | P52333 | 2/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13059474 | 0.94 | MAPK1 (0.31) | — | |
| SCHEMBL13060037 | 0.91 | — | — | |
| SCHEMBL2633646 | 0.91 | — | — | |
| SCHEMBL10068274 | 0.90 | CTSK (0.32) | — | |
| SCHEMBL10067629 | 0.88 | TRPV3 (0.31) | JAK1 | |
| SCHEMBL10067630 | 0.88 | TRPV3 (0.31) | JAK1 | |
| SCHEMBL13060174 | 0.83 | ROCK2 (0.36) | JAK1JAK2TYK2JAK3LOXL2 | |
| SCHEMBL2633577 | 0.82 | ROCK2 (0.47) | JAK1JAK2TYK2JAK3IP6K1 | |
| SCHEMBL10067701 | 0.81 | HTRA1 (0.33) | — | |
| SCHEMBL13214995 | 0.80 | IDO1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165307-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165307-A1 | AZAINDOLES USEFUL AS INHIBITORS OF JANUS KINASES | JAK3, JAK1, JAK2 | JAK1 2/4885JAK2 3/4885TYK2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.